[1] Diabetes World Health Organization , http://www. who. int/mediacentre/fa-ctsheets/fs312/en/.[2] RASMUSSEN H B, BRANNER S, WIBERG F C, et al. Crystal structure of human dipeptidyl peptidase 4/CD26 in complex with a substrate analog . Nat Struct Biol, 2003, 10(1):19-25.[3] AHRN B. Inhibition of dipeptidyl peptidase-4(DPP-4)-a novel approach to treat type 2 diabetes . Curr Enz Inhib, 2005, 1(1):65-73.[4] ZHANG X Y, GAO W E. Dipeptidyl peptidase 4 inhibitors as new drugs for the treatment of type 2 diabetes . Chin Pham J (中国药学杂志), 2007, 42(16):1204-1207.[5] ZHU Y, FU D X. Progress on dipeptidyl peptidase 4 inhibitors . Chin Pham J(中国药学杂志), 2007, 42(17):1284-1287.[6] JIAO W, ZHU C, LAI Y, et al. Research advances on dipeptidyl peptidase inhibitors . Prog Pharm Sci (药学进展),2008,32(7):289-296.[7] SHRIKANTH H H, MANOJIT P. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes . Bioorg Med Chem, 2009, 17(5):1783-1802.[8] ASHWORTH D M, ATRASH B, BAKER G R, et al. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase 4 . Bioorg Med Chem Lett, 1996, 6(10):1163-1166.[9] VILLHAUER E B, BRINKMAN J A, NADERI G B, et al. 1-[2-ethylamino]acetyl-2-(S)-pyrrolidinecarbon itrile:A potent, select4e, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties . J Med Chem, 2002, 45(12):2362-2365.[10] AHREN B, SIMONSSON E, LARSSON H, et al. Inhibition of dipeptidyl peptidase 4 improves metabolic control over a 4-Week study period in type 2 diabetes . Diabetes Care, 2002, 25(5):869-875.[11] VILLHAUER E B, BRINKMAN J A, NADERI G B, et al. 1-[acetyl] -2-cyano-(S)-pyrrolidine:A potent, selective, and orally bioavailable dipeptidyl peptidase 4 inhibitor with antihyperglycemic properties . J Med Chem, 2003, 46(13):2774-2789.[12] ROYALTY S M, BURNS J F, SCICINSKI J J, et al. Peptidase Inhibitors:America, WO2006012395 . 2006-02-02.[13]TSAI T Y, HSU T, CHEN C T, et al. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors . Bioorg Med Chem Lett, 2009, 19(7):1908-1912.[14]KATO N, OKA M, MURASE T, et al. Discovery and pharmacological characterization of N-[2-({2--2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolopyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor . Bioorg Med Chem, 2011, 19(23):7221-7227.[15] WANG L, ZHANG B, JI J, et al. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors . Eur J Med Chem, 2009, 44(8):3318-3322.[16] CHO T P, LONG Y F, GANG L Z, et al. Synthesis and biological evaluation of azobicyclo octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes . Bioorg Med Chem Lett, 2010, 20(12):3565-3568.[17] JADAV P, BAHEKAR R, SHAH S R, et al. Long-acting peptidomimetics based DPP-IV inhibitors . Bioorg Med Chem Lett, 2012, 22(10):3516-3521.[18] AUGERI D J, ROBL J A, BETEBENNER D A, et al. Discovery and preclinical profile of saxagliptin (BMS-477118):A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes . J Med Chem, 2005, 48(15):5025-5037.[19] ZHAO G, TAUNK P C, MAGNIN D R, et al. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors . Bioorg Med Chem Lett, 2005, 15(18):3992-3995.[20] HAFFNER C D, MCDOUGALD D L, REISTER S M, et al. 2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV . Bioorg Med Chem Lett, 2005, 15(23):5257-5261.[21] TAI T Y, HSU T, CHEN C T, et al. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors . Bioorg Med Chem, 2009, 17(6):2388-2399.[22] YEH T K, TAI T Y, HSU T, et al. (2S,4S)-1--4-fluoro-pyrrolidine-2-carbonitrile:A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV . Bioorg Med Chem Lett, 2010, 20(12):3596-3600. [23] SORBERA L A, REVEL L, CASTANER J. Antidiabetic, dipeptidyl-peptidase IV inhibitor . Drugs Fut, 2001, 26(9):859.[24] PARMEE E R, HE J, MASTRACCHIO A, et al. 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors . Bioorg Med Chem Lett, 2004, 14(1):43-46.[25] YOSHIDA T, AKAHOSHI F, SAKASHITA H, et al. Discovery and preclinical proflle of teneligliptin (3-[(2S,4S)-4-pyrrolidin-2-ylcarbonyl]thiazolidine):A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes . Bioorg Med Chem, 2012, 20(19):5705-5719.[26] EDMONDSON S D, MASTRACCHIO A, MATHVINK R J, et al. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl) -N,N-dimethyl-4-oxo-2-(4-triazolo-pyridin-6-ylphenyl)butanamide:A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes . J Med Chem, 2006, 49(12):3614-3627.[27] DUFFY J L, KIRK B A, WANG L, et al. 4-Aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV . Bioorg Med Chem Lett, 2007, 17(10):2879-2885.[28] KAELIN D E, SMENTON A L, EIERMANN G J, et al. 4-Arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV . Bioorg Med Chem Lett, 2007, 17(21):5806-5811.[29] XU J, WEI L, MATHVINK R J, et al. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors . Bioorg Med Chem Lett, 2006, 16(20):5373-5377.[30] AMMIRATI M J, ANDREWS K M, BOYER D D, et al. (3,3-Difluoro-pyrrolidin-1-yl)-methanone:A potent, selective, orally active dipeptidyl peptidase IV inhibitor . Bioorg Med Chem Lett, 2009, 19(7):1991-1995.[31] VILLHAUER E B, BRINKMAN J A, NADERI G B, et al. 1-[acetyl] -2-cyano-(S)-pyrrolidine:A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties . J Med Chem, 2003, 46(13):2774-2789.[32] WU W, LIU Y, MILO L J, et al. 4-Substituted boro-proline dipeptides:Synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities . Bioorg Med Chem Lett, 2012, 22(17):5536-5540. [33] SNOW R I, BACHOVCHIN W W. Boronic acid inhibitors of dipeptidyl peptidase IV:A new class of immunosuppressive agents . Adv Med Chem, 1995, 3:149-177.[34] KIM D, KOWALCHICK J E, EDMONDSON S D, et al. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors:Close analogs of JANUVIA^TM (sitagliptin phosphate) . Bioorg Med Chem Lett, 2007, 17(12):3373-3377.[35] KIM D, KOWALCHICK J E, BROCKUNIER L L, et al. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing subsitutedtriazolopiperazines . J Med Chem, 2008, 51(3):589-602.[36] BIFTU T, FENG D, QIAN X, et al. (3R)-4--3-(2,2,2- trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes . Bioorg Med Chem Lett, 2007, 17(1):49-52.[37] NORDHOFF S, LOPEZ-CANET M, HOFFMANN-ENGER B, et al. From lead to preclinical candidate:Optimization of β-homophenylalanine based inhibitors of dipeptidyl peptidase IV . Bioorg Med Chem Lett, 2009, 19(16):4818-4823.[38] ZHU Y, XIA S, ZHU M, et al. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors . Eur J Med Chem, 2010, 45(11):4953-4962.[39] KIM H J, KWAK W Y, MIN J P, et al. Discovery of DA-1229:A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes . Bioorg Med Chem Lett, 2011, 21(12):3809-3812.[40] PARK W S, KANG S K, JUN M A, et al. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors . Bioorg Med Chem Lett, 2011, 21(5):1366-1370.[41] ECKHARDT M, LANGKOPF E, MARK M, et al. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes . J Med Chem, 2007, 50(26):6450-6453.[42] FENG J, ZHANG Z, WALLACE M B, et al. Discovery of Alogliptin:A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV . J Med Chem, 2007, 50(10):2297-2300.[43] SCHOENAFINGER K, JAEHNE G, DEFOSSsA E, et al. Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments:Germany,WO06015701 . 2006.[44] NISHIO Y, KIMURA H, SAWADA N, et al. 2-({6--1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolopyrimidine-5-yl}methyl)-4-fluorobenzonitrile(DSR-12727):A potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A . Bioorg Med Chem, 2011, 19(18):5490-5499.[45] MATTEI P, BOEHRINGER M, GIORGIO P D, et al. Discovery of carmegliptin:A potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes . Bioorg Med Chem Lett, 2010, 20(3):1109-1113.[46] CHEN P, CALDWELL C G, ASHTON W, et al. Synthesis and evaluation of cyclohexanes and 4-piperidines as DPP-4 inhibitors . Bioorg Med Chem Lett, 2011, 21(6):1880-1886.[47] XIE H, ZENG L, ZENG S, et al. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization . Eur J Med Chem, 2012, 52:205-212.[48] SUTTON J M, CLARK D E, DUNSDON S J, et al. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes . Bioorg Med Chem Lett, 2012, 22(3):1464-1468. [49]IKUMA Y, HOCHIGAI H, KIMURA H, et al. Discovery of ³H-imidazoquinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors . Bioorg Med Chem, 2012, 20(19):5864-5883.[50] BRIGANCE R P, MENG W, FURA A, et al. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase 4(DPP4) inhibitors for type 2 diabetes . Bioorg Med Chem Lett, 2010, 20(15):4395-4398.[51] MOTOSHIMA K, SUGITA K, HASHIMOTO Y, et al. Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists . Bioorg Med ChemLett, 2011, 21(10):3041-3045.[52] BANNO Y, MIYAMOTO Y, SASAKI M, et al. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones:A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554 . Bioorg Med Chem, 2011, 19(16):4953-4970.[53] MAEZAKI H, BANNO Y, MIYAMOTO Y, et al. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554 . Bioorg Med Chem, 2011, 19(15):4482-4498.[54] MIYAMOTO Y, BANNO Y, YAMOSHITA T, et al. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125 . Bioorg Med Chem, 2011, 19(1):172-185.[55] PAN C, YANG W, BARONA J P, et al. Comparison of vildagliptin and acarbosemonotherapy in patients with type 2 diabetes:A 24-week, double-blind, randomized trial . Diabet Med, 2008, 25(4):435-441.[56] FILOZOF C, GAUTIER J F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone:A 52-week, randomized study . Diabet Med, 2010, 27(3):318-326. [57]ROSENSTOCK J, AGUILAR-SALINAS C, KLEIN E, et al. Effect of saxagliptinmonotherapy in treatment-naive patients with type 2 diabetes . Curr Med Res Opin, 2009, 25(10):2401-2411.[58] DEFRONZO R A, HISSA M N, GARBER A J, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone . Diabetes Care, 2009, 32(9):1649-1655.[59] ASCHNER P, KIPNES M S, LUNCEFORD J K, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes . Diabetes Care, 2006, 29(12):2632-2637.[60] NONAKA K, KAKIKAWA T, SATO A, et al. Efficacy and safety of sitagliptinmonotherapy in Japanese patients with type 2 diabetes . Diabetes Res Clin Pract, 2008, 79(2):291-298.[61] CHARBONNEL B, KARASIK A, LIU J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone . Diabetes Care, 2006, 29(12):2638-2643.